
Clarametyx Biosciences Reports Advancements in CMTX-101 Antibody Therapy for Cystic Fibrosis Infections
Clarametyx Biosciences Moves Forward with Phase 2a Study of CMTX-101 for Cystic Fibrosis Infections Clarametyx Biosciences, Inc. has successfully completed the Phase 1b portion of its clinical trial for CMTX-101,…













